Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Bipolar Disorders, Journal Year: 2018, Volume and Issue: 20(2), P. 97 - 170

Published: March 1, 2018

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines bipolar disorder in 2005, along with international commentaries subsequent updates 2007, 2009, 2013. last two were collaboration the International Society Bipolar Disorders (ISBD). These 2018 CANMAT ISBD Treatment Guidelines represent significant advances field since full edition was including to diagnosis management as well new research into pharmacological psychological treatments. have been translated clear easy use recommendations first, second, third- line treatments, consideration given levels of evidence efficacy, clinical support based on experience, consensus ratings safety, tolerability, treatment-emergent switch risk. New these guidelines, hierarchical rankings created first second- treatments recommended acute mania, depression, maintenance I disorder. Created by considering impact each across all phases illness, this hierarchy will further assist clinicians making evidence-based decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, cariprazine alone or combination are first-line mania. First-line options depression include lurasidone plus lithium lithium, lamotrigine, lurasidone, adjunctive lamotrigine. While medications that shown be effective phase should generally continued disorder, there some exceptions (such antidepressants); available data suggest aripiprazole monotherapy considered those initiating switching during phase. In addition addressing issues also provide an overview of, for, II advice specific populations, such women at various stages reproductive cycle, children adolescents, older adults. There discussions psychiatric medical comorbidities substance use, anxiety, metabolic disorders. Finally, related safety monitoring is provided. groups hope become a valuable tool practitioners globe.

Language: Английский

---

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

Journal of Psychopharmacology, Journal Year: 2016, Volume and Issue: 30(6), P. 495 - 553

Published: March 15, 2016

The British Association for Psychopharmacology guidelines specify the scope and target of treatment bipolar disorder. second version, like first, is based explicitly on available evidence presented, previous Clinical Practice guidelines, as recommendations to aid clinical decision making practitioners: they may also serve a source information patients carers. are presented together with more detailed but selective qualitative review evidence. A consensus meeting, involving experts in disorder its treatment, reviewed key areas considered strength implications. were drawn up after extensive feedback from participants interested parties. supporting was rated. cover diagnosis disorder, management, strategies use medicines episodes, relapse prevention stopping treatment.

Language: Английский

---

What Is a “Mood Stabilizer”? An Evidence-Based Response

American Journal of Psychiatry, Journal Year: 2004, Volume and Issue: 161(1), P. 3 - 18

Published: Jan. 1, 2004

OBJECTIVE: The term "mood stabilizer" is widely used in the context of treating bipolar disorder, but U.S. Food and Drug Administration (FDA) does not officially recognize term, no consensus definition accepted among investigators. authors propose a "two-by-two" by which an agent considered mood stabilizer if it has efficacy acute manic depressive symptoms prophylaxis disorder. They review literature on agents any these four roles to determine meet this stabilizer. METHOD: conducted comprehensive English-language describing peer-reviewed, Agency for Healthcare Research Quality class A controlled trials order identify with included their were classified as positive or negative basis primary outcome variables. An "FDA-like" criterion at least two placebo-controlled was required consider efficacious. also sensitivity analysis raising relaxing criteria including review. RESULTS: identified 551 candidate articles, yielding 111 trials, 81 monotherapy 95 independent analyses published through June 2002. Lithium, valproate, olanzapine had unequivocal evidence episodes, lithium episodes mania depression, lamotrigine (relapse polarity unspecified). Thus, only fulfilled priori Relaxing quality did change finding, while threshold resulted fulfilling definition. CONCLUSIONS: When all treatment are considered, supported role first-line highlights unmet needs promising provides yardstick evaluating new strategies.

Language: Английский

---

Treatment of bipolar disorder

The Lancet, Journal Year: 2013, Volume and Issue: 381(9878), P. 1672 - 1682

Published: May 1, 2013

Language: Английский

---

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Australian & New Zealand Journal of Psychiatry, Journal Year: 2015, Volume and Issue: 49(12), P. 1087 - 1206

Published: Dec. 1, 2015

Objectives: To provide guidance for the management of mood disorders, based on scientific evidence supplemented by expert clinical consensus and formulate recommendations to maximise salience utility. Methods: Articles information sourced from search engines including PubMed EMBASE, MEDLINE, PsycINFO Google Scholar were literature known disorders committee (MDC) (e.g., books, book chapters government reports) published depression bipolar disorder guidelines. Information was reviewed discussed members MDC findings then formulated into consensus-based guidance. The guidelines subjected rigorous successive consultation external review involving: advisors, public, key stakeholders, professional bodies specialist groups with interest in disorders. Results: Royal Australian New Zealand College Psychiatrists practice (Mood Disorders CPG) up-to-date advice regarding that is informed experience. Mood CPG intended use psychiatrists, psychologists, physicians others an mental health care. Conclusions: Disorder first Clinical Practice Guideline address both depressive It provides within evidence-based framework, consensus. Committee: Professor Gin Malhi (Chair), Darryl Bassett, Philip Boyce, Richard Bryant, Paul Fitzgerald, Dr Kristina Fritz, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Porter Associate Ajeet Singh. International advisors: Carlo Altamura, Francesco Colom, Mark George, Guy Goodwin, McIntyre, Ng, John O’Brien, Harold Sackeim, Jan Scott, Nobuhiro Sugiyama, Eduard Vieta, Lakshmi Yatham. Marie-Paule Austin, Michael Berk, Yulisha Byrow, Helen Christensen, Nick De Felice, A/Professor Seetal Dodd, Megan Galbally, Josh Geffen, Hazell, David Horgan, Felice Jacka, Gordon Johnson, Anthony Jorm, Jon-Paul Khoo, Jayashri Kulkarni, Cameron Lacey, Noeline Latt, Florence Levy, Andrew Lewis, Colleen Loo, Thomas Mayze, Linton Meagher, Mitchell, Daniel O’Connor, Tim Outhred, Rowe, Narelle Shadbolt, Martien Snellen, Tiller, Watkins, Raymond Wu.

Language: Английский

---

A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness

New England Journal of Medicine, Journal Year: 2013, Volume and Issue: 368(17), P. 1594 - 1602

Published: March 21, 2013

Overweight and obesity are epidemic among persons with serious mental illness, yet weight-loss trials systematically exclude this vulnerable population. Lifestyle interventions require adaptation in group because psychiatric symptoms cognitive impairment highly prevalent. Our objective was to determine the effectiveness of an 18-month tailored behavioral intervention adults illness.We recruited overweight or obese from 10 community rehabilitation outpatient programs randomly assigned them a control group. Participants received individual weight-management sessions exercise sessions. Weight change assessed at 6, 12, 18 months.Of 291 participants who underwent randomization, 58.1% had schizophrenia schizoaffective disorder, 22.0% bipolar 12.0% major depression. At baseline, mean body-mass index (the weight kilograms divided by square height meters) 36.3, 102.7 kg (225.9 lb). Data on months were obtained 279 participants. loss increased progressively over study period differed significantly each follow-up visit. months, between-group difference (change minus group) -3.2 (-7.0 lb, P=0.002); 37.8% lost 5% more their initial weight, as compared 22.7% those (P=0.009). There no significant differences adverse events.A reduced illness. Given weight-related disease our findings support implementation targeted high-risk (Funded National Institute Mental Health; ACHIEVE ClinicalTrials.gov number, NCT00902694.).

Language: Английский

---

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

The British Journal of Psychiatry, Journal Year: 2012, Volume and Issue: 200(2), P. 97 - 106

Published: Feb. 1, 2012

The efficacy of psychopharmacological treatments has been called into question. Psychiatrists are unfamiliar with the effectiveness common medical drugs.To put psychiatric drugs perspective that major drugs.We searched Medline and Cochrane Library for systematic reviews on compared placebo disorders, systematically presented effect sizes primary outcomes.We included 94 meta-analyses (48 in 20 diseases, 16 8 disorders). There were some general clearly higher than psychotropic agents, but not generally less efficacious other drugs.Any comparison different outcomes diseases can only serve purpose a qualitative perspective. increment improvement by drug over must be viewed context disease's seriousness, suffering induced, natural course, duration, outcomes, adverse events societal values.

Language: Английский

---

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

Bipolar Disorders, Journal Year: 2005, Volume and Issue: 7(s3), P. 5 - 69

Published: June 1, 2005

Since the previous publication of Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines in 1997, there has been a substantial increase evidence‐based treatment options bipolar disorder. The present review new evidence use criteria to rate strength incorporate effectiveness, safety, tolerability data determine global clinical recommendations various phases suggest that although pharmacotherapy forms cornerstone management, utilization adjunctive psychosocial treatments incorporation chronic disease management model involving healthcare team are required providing optimal patients with Lithium, valproate several atypical antipsychotics first‐line acute mania. Bipolar depression mixed states frequently associated suicidal acts; therefore assessment suicide should always be an integral part managing any patient. lamotrigine or combinations antidepressant mood‐stabilizing agents depression. First‐line maintenance disorder lithium, lamotrigine, olanzapine. Historical symptom profiles help selection. With growing recognition II disorders, it is anticipated larger body will become available guide this common disabling condition. These also discuss issues related women those comorbidity include section on safety monitoring.

Language: Английский

---

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder

Cochrane library, Journal Year: 2013, Volume and Issue: unknown

Published: Oct. 17, 2013

Language: Английский

---

Interventions for self-harm in children and adolescents

Cochrane library, Journal Year: 2015, Volume and Issue: 2021(9)

Published: Dec. 21, 2015

Language: Английский

---